I was diagnosed January 2022. Started Adempas soon after. I did have a few side effects that I worked through. I feel much better now. I also take Uptravi. The fluid pills as needed. Not sure what your question was.
June 14, 2024
Adempas (Riociguat) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise and function in adult cases of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Here are some key points about Adempas:
- Class: Soluble guanylate cyclase Show Full Answer
Adempas (Riociguat) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise and function in adult cases of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Here are some key points about Adempas:
- Class: Soluble guanylate cyclase stimulators (SGCS).
- Mechanism: Stimulates the action of an enzyme called soluble guanylate cyclase, which dilates blood vessels, specifically the pulmonary arteries.
- Dosage: Taken three times a day in tablet form.
- Side Effects: Common side effects include headache, dizziness, low blood pressure, upset stomach, stomach pain, anemia, gastric reflux, nausea, diarrhea, vomiting, and constipation. Rare but serious side effects include severe birth defects, bleeding, severe hypotension, and pulmonary edema.
- Special Program: Due to its potential to cause severe birth defects, Adempas is only available to female consumers through a limited distribution program called the Adempas Risk Evaluation and Mitigation Strategies (REMS) Program.
For more details, you can visit the [Adempas page on myPHteam](https://www.myPHteam.com/treatments/adempas).
June 13, 2024